Melanoma is the most common lethal cutaneous neoplasm. In order to harmonize treatment and follow-up of melanoma patients, guidelines for the management of melanoma in Switzerland have been inaugurated in 2001. These have been approved by all Swiss medical societies involved in the care of melanoma patients. New data necessitated changes concerning the safety margins (reduction to maximally 2 cm) and modifications of the recommendations of follow-up.

1.
Garbe C, Dummer R, Kaufmann R, Tilgen W: Dermatologische Onkologie. Berlin, Springer, 1997.
2.
Dummer R, Bosch U, Panizzon R, Bloch PH, Burg G: Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2001;203:75–80.
3.
Australian Cancer Network: Guidelines for the Management of Cutaneous Melanoma. Sydney, Stone Press, 1997.
4.
Panizzon RG, Guggisberg D: Klinik und Pathologie des Melanoms. Ther Umsch 1999;56:302–308.
5.
Grob JJ, Bonerandi JJ: The ‘ugly duckling’ sign: Identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998;134:103–104.
6.
Binder M, Puespoeck Schwarz M, Steiner A, Kittler H, Muellner M, Wolff K, et al: Epiluminescence microscopy of small pigmented skin lesions: Short-term formal training improves the diagnostic performance of dermatologists. J Am Acad Dermatol 1997;36(2, pt 1):197–202.
7.
Haffner AC, Garbe C, Burg G, Buttner P, Orfanos CE, Rassner G: The prognosis of primary and metastasising melanoma: An evaluation of the TNM classification in 2,495 patients. Br J Cancer 1992;66:856–861.
8.
Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, et al: A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000;88:1484–1491.
9.
Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al: Final version of the American Joint Committee on Cancer Staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635–3648.
10.
Kaufmann R, Tilgen W, Garbe C: Malignant melanoma. Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists eV. Hautarzt 1998;48(suppl 1):S30–S38.
11.
Farshad A, Burg G, Panizzon R, Dummer R: A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using grenz or soft X-rays. Br J Dermatol 2002;146:1042–1046.
12.
Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–399.
13.
Kleeberg UR, Suciu S, Broecker EB, Ruiter DJ, Chartier C, Liénard D, et al: Final results of the EORTC 18871/DKG 80–1 randomised phase III trial: rIFN-alpha 2b versus rIFN-gamma versus Iscador M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004;40:390–402.
14.
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17.
15.
Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, et al: High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group phase II trial E2696. J Clin Oncol 2001;19:1430–1436.
16.
Eggermont AM: Critical appraisal of IFN-alpha-based adjuvant therapy in stage II–III malignant melanoma. Expert Rev Anticancer Ther 2002;2:563–569.
17.
Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol 2002;20:1818–1825.
18.
Lejeune F, Lienard D, Eggermont A, Schraffordt Koops H, Kroon B, Gerain J, et al: Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma. Circ Shock 1994;43:191–197.
19.
Huncharek M, Caubet JF, McGarry R: Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-analysis of 3,273 patients from 20 randomized trials. Melanoma Res 2001;11:75–81.
20.
Jager D, Jager E, Knuth A: Vaccination for malignant melanoma: Recent developments. Oncology 2001;60:1–7.
21.
Jansen B, Wacheck V, Heere Ress E, Schlagbauer Wadl H, Hoeller C, Lucas T, et al: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000;356:1728–1733.
22.
Poo Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, et al: Follow-up recommendations for patients with American Joint Committee on Cancer stages I–III malignant melanoma. Cancer 1999;86:2252–2258.
23.
Agarwala SS, Glaspy J, O’Day SJ, Mitchell M, Gutheil J, Whitman E, et al: Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002;20:125–133.
24.
Orfanos CE, Jung EG, Rassner G, Wolff HH, Garbe C: Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut – Stand 1993/94. Hautarzt 1994;45:285–291.
25.
Garbe C, Paul A, Kohler Spath H, Ellwanger U, Stroebel W, Schwarz M, et al: Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: Recommendations for an effective follow-up strategy. J Clin Oncol 2003;21:520–529.
26.
von Schulthess GK, Steinert HC, Dummer R, Weder W: Cost-effectiveness of whole-body PET imaging in non-small cell lung cancer and malignant melanoma. Acad Radiol 1998;5:S300–S302.
27.
Henze G, Dummer R, Joller Jemelka HI, Boni R, Burg G: Serum S100 – A marker for disease monitoring in metastatic melanoma. Dermatology 1997;194:208–212.
28.
Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, et al: Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999;140:1065–1071.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.